Scribe Therapeutics posts Q3 2026 results after IPO; STX-1150 Phase 1 data due first half 2027
On November 12, 2026, Scribe Therapeutics reported Q3 results, with $174.2 million in cash after a July Nasdaq IPO and concurrent Sanofi private placement raising $155.5 million gross. Enrollment continues in the first-in-human Phase 1 trial of STX-1150, an epigenetic PCSK9-silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027. The company also expanded its Sanofi collaboration to include its ELXR silencing technology and presented preclinical data on STX-1150 and STX-1200 (Lp(a)).
Company's press release (SEC filing): Scribe Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants
Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
